Tographs on a 7 point scale separatelybased Bleomycin Blenoxane Declined sharply 3, 2 m reduced strength, a slight decrease, 0 no change Ver, a slightly elevated ht, 2 m ig greatly increased.The score 3, Don t know erh hte, was used in technical issues with the photos is not an accurate phone start up allow estimation. Safety assessments Safety assessments included clinical and laboratory findings and reports of side effects. Statistical analyzes of efficacy analyzes at 12 and 24 months were on a modified intention treat population at the base. In the two year study of M Nnern the age of 41 to 60 years and added a two year study of M Nnern in age from 18 to 41 was the modified intent to treat population included all Patients were randomized to re defined u is at least one dose of study medication, double blind, and had at least one post baseline measurement. The Verl EXTENSIONS study over 1 year for M Men aged 18 to 41 the modified intent to treat population as all M Men, Ma said at least one exception In the second year had been defined. The last observation was carried forward to impute missing data, but at M Nnern aged 18 to 41 years was no data between the first baseline study and extension of the first study reported. S Mtliche Moxifloxacin Topoisomerase inhibitor analyzes presented in this report given, including the combination of data from the two original studies on M Nnern aged 18 to 41 years to ensure the accuracy of the Sch Estimates of the effect of improving the treatment.
Efficacy endpoints are descriptive than average residence Change from baseline in the photographic assessment of the combined scale of 7 points based, and the percentage of Dienogest Natazia Estrogen/progestin receptor inhibitor patients receiving each score for each area of the scalp after 12 and 24 months. An analysis of variance model, the conditions for the site and the treatment was involved used the photographic analyzed by the average rating of scores for each treatment group at any time. All statistical tests were two sided and starts Rt were statistically significant at the.05. All P values were made adjustments for nominaleno variety. And safety reps Were evaluated by statistical analysis of opportunity and adverse events and clinical laboratory values within 3 studies, as reported previously.8, 9,13 treatment results basic properties of Table I summarizes the baseline characteristics of patients. The average age for M Men were aged 18 to 41 in 33 years. The average age for M Men was aged 41 to 60 years 50 years. The average age at which patients began to lose her hair was 24 and 35 years in groups aged 18 41 years and 41 60 years. The entire study population for M Men aged 18 to 60 years was generally well balanced with respect to the Cidofovir classification of Norwood / Hamilton between the two treatment groups.
As expected, has M Men in Older group h Forth on the scale of Norwood / Hamilton MPHL as M Men in the age group. The study population of the men aged 18 to 41 years were Similar TimeIn between baseline characteristics of the entire study population and the cohort that again U finasteride or placebo in year 1 and year 2. Overall photographic vertex. As already mentioned, 8,9,13 photographic overall assessment of the scalp vertex showed a statistically significant improvement compared to placebo in the reporting of head hair nnern in young M And Treated older finasteride t more.